These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 32031899)

  • 1. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
    Rosenberg J; Sridhar SS; Zhang J; Smith D; Ruether D; Flaig TW; Baranda J; Lang J; Plimack ER; Sangha R; Heath EI; Merchan J; Quinn DI; Srinivas S; Milowsky M; Wu C; Gartner EM; Zuo P; Melhem-Bertrandt A; Petrylak DP
    J Clin Oncol; 2020 Apr; 38(10):1041-1049. PubMed ID: 32031899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
    Rosenberg JE; O'Donnell PH; Balar AV; McGregor BA; Heath EI; Yu EY; Galsky MD; Hahn NM; Gartner EM; Pinelli JM; Liang SY; Melhem-Bertrandt A; Petrylak DP
    J Clin Oncol; 2019 Oct; 37(29):2592-2600. PubMed ID: 31356140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
    Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
    Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
    Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
    Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
    Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP
    N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
    McGregor B; O'Donnell PH; Balar A; Petrylak D; Rosenberg J; Yu EY; Quinn DI; Heath EI; Campbell M; Hepp Z; McKay C; Steinberg J; Regnault A; Mazerolle F; Galsky MD
    Eur Urol; 2022 May; 81(5):515-522. PubMed ID: 35168844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enfortumab vedotin to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
    McGregor BA; Sonpavde G
    Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
    [No Abstract]   [Full Text] [Related]  

  • 9. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
    Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
    Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
    Lacouture ME; Patel AB; Rosenberg JE; O'Donnell PH
    Oncologist; 2022 Mar; 27(3):e223-e232. PubMed ID: 35274723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enfortumab Vedotin in urothelial cancer.
    Alt M; Stecca C; Tobin S; Jiang DM; Sridhar SS
    Ther Adv Urol; 2020; 12():1756287220980192. PubMed ID: 33447264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enfortumab vedotin - next game-changer in urothelial cancer.
    Maas M; Stühler V; Walz S; Stenzl A; Bedke J
    Expert Opin Biol Ther; 2021 Jul; 21(7):801-809. PubMed ID: 33325754
    [No Abstract]   [Full Text] [Related]  

  • 13. Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma.
    Tomiyama E; Fujita K; Rodriguez Pena MDC; Taheri D; Banno E; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Takao T; Yamaguchi S; Fushimi H; Yoshimura K; Uemura H; Netto GJ; Nonomura N
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
    Halford Z; Anderson MK; Clark MD
    Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma.
    Matsubara N; Yonese J; Kojima T; Azuma H; Matsumoto H; Powles T; Rosenberg JE; Petrylak DP; Matsangou M; Wu C; Campbell M; Yamashiro M
    Cancer Med; 2023 Feb; 12(3):2761-2771. PubMed ID: 36052536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
    Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
    Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin.
    Curran C; Adib E; Kazakova V; Grivas P; Diamantopoulos LN; Alva AS; Su C; Jain RK; Tandon A; Necchi A; Marandino L; Plastini TM; Merchan JR; Sonpavde G
    Clin Genitourin Cancer; 2022 Feb; 20(1):11-16. PubMed ID: 34503934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enfortumab vedotin in the treatment of urothelial cancers and beyond.
    Wong RL; Yu EY
    Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
    Heath EI; Rosenberg JE
    Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
    Klümper N; Ralser DJ; Ellinger J; Roghmann F; Albrecht J; Below E; Alajati A; Sikic D; Breyer J; Bolenz C; Zengerling F; Erben P; Schwamborn K; Wirtz RM; Horn T; Nagy D; Toma M; Kristiansen G; Büttner T; Hahn O; Grünwald V; Darr C; Erne E; Rausch S; Bedke J; Schlack K; Abbas M; Zschäbitz S; Schwab C; Mustea A; Adam P; Manseck A; Wullich B; Ritter M; Hartmann A; Gschwend J; Weichert W; Erlmeier F; Hölzel M; Eckstein M
    Clin Cancer Res; 2023 Apr; 29(8):1496-1505. PubMed ID: 36534531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.